Valérie Ortonne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Valérie Ortonne has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Giovana Melica
Department of Infectious Diseases, hôpital Henri Mondor, 94000 Créteil, France
1 shared publication - Jean-Dominique Poveda
Laboratoire Cerba, Department of Infectious Diseases, 95310 Cergy-Pontoise, France
1 shared publication - Jean-Michel Pawlotsky
IMRB INSERM U955, Team « Viruses, Hepatology, Cancer », Université Paris-Est-Créteil (UPEC) , Créteil
1 shared publication - Magali Bouvier-Alias
Department of Virology, Henri Mondor Hospital, National Reference Center for Viral Hepatitis B, C and delta D, INSERMU955 , Créteil
1 shared publication - Mélanie Wlassow
National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, hôpital Henri Mondor, Université Paris-Est, 94000 Créteil, France
1 shared publication - Stéphane Chevaliez
Department of Virology, French National Reference Center for Hepatitis B, C and D Viruses, Hôpital Henri Mondor (AP-HP), Université Paris-Est, Créteil, France
1 shared publication
Latest Publications
- Open Access
- 11 March 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (3) , 573
Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas® HBV Test for Use on the Cobas® 4800 System
(1) Background: Sensitive and accurate nucleic acid amplification technologies are now recommended for hepatitis B virus (HBV) DNA detection and quantification in clinical practice to diagnose and monitor hepatitis B infection. The aim of this study was to assess the analytical and clinical performance of the cobas® HBV Test on the cobas® 4800 System. (2) Methods: Standard panel and clinical specimens were tested in parallel with three different real-time commercial PCR assays including the cobas ® HBV Test, the Cobas® AmpliPrep/Cobas® TaqMan HBV Test v2.0 and Alinity™ m HBV assay. (3) Results: The specificity of the cobas® HBV Test was 97.9%. The limit of detection was estimated to be 2.1 IU/mL. Intra-assay and interassay coefficients of variation varied from 0.14% to 1.92% and 2.16% to 12.02%, respectively. HBV DNA levels in patients infected with different HBV genotypes strongly correlated with those measured by the two other commercial comparators assays. (4) Conclusions: The cobas® HBV Test can be confidently used to detect and accurately quantify HBV DNA in clinical practice as well as in clinical trials with the new anti-HBV drugs currently in development.
- 11 March 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (3) , 573
Open AccessDiagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas® HBV Test for Use on the Cobas® 4800 System
(1) Background: Sensitive and accurate nucleic acid amplification technologies are now recommended for hepatitis B virus (HBV) DNA detection and quantification in clinical practice to diagnose and monitor hepatitis B infection. The aim of this study was to assess the analytical and clinical performance of the cobas® HBV Test on the cobas® 4800 System. (2) Methods: Standard panel and clinical specimens were tested in parallel with three different real-time commercial PCR assays including the cobas ® HBV Test, the Cobas® AmpliPrep/Cobas® TaqMan HBV Test v2.0 and Alinity™ m HBV assay. (3) Results: The specificity of the cobas® HBV Test was 97.9%. The limit of detection was estimated to be 2.1 IU/mL. Intra-assay and interassay coefficients of variation varied from 0.14% to 1.92% and 2.16% to 12.02%, respectively. HBV DNA levels in patients infected with different HBV genotypes strongly correlated with those measured by the two other commercial comparators assays. (4) Conclusions: The cobas® HBV Test can be confidently used to detect and accurately quantify HBV DNA in clinical practice as well as in clinical trials with the new anti-HBV drugs currently in development.